secwatch.observer — SEC 8-K summary
======================================

Issuer:     Thorne Healthtech, Inc. (—)
CIK:        0001844280
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0000950170-23-048594
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Thorne HealthTech receives Nasdaq delisting notice, appoints new independent director amid pending merger
--------------------------------------------------------------------------------

- Received Nasdaq notice Sept 11, 2023 for non-compliance with Rule 5605 (majority independent directors) due to resignation of director Takeshi Minakata effective Aug 15.
- Cure period expires earlier of next annual meeting or April 1, 2024; if annual meeting before Sept 28, 2023, then by Sept 28.
- Company not actively working to regain compliance due to pending acquisition at $10.20 per share under Merger Agreement dated Aug 27, 2023.
- On Sept 2, 2023, Board appointed Toshitaka Inuzuka as independent director and third member of Audit Committee, expecting to regain audit committee compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844280/000095017023048594/0000950170-23-048594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844280/000095017023048594/thrn-20230902.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-048594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer